Vanguard Capital Management
LPCN icon

Vanguard Capital Management’s Lipocine LPCN Stock Holding History

Vanguard Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$591K Buy
230,823
+30,155
+15% +$72.5K ﹤0.01% 3688
2026
Q1 		$1.6M Buy
+200,668
New +$1.75M ﹤0.01% 3434

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management's LPCN Position: Q2 2026 in Review

Vanguard Capital Management increased its Lipocine (LPCN) stake by 15% in Q2 2026, buying an estimated $72.5K and bringing the position to 230,823 shares worth $591K. The position accounts for ﹤0.01% of the portfolio, ranked #3688.

Vanguard Capital Management first reported a position in LPCN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.6M in Q1 2026. 34 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Vanguard Capital Management held 230,823 shares of Lipocine worth $591K as of Q2 2026.
  • Vanguard Capital Management bought 30,155 Lipocine shares in Q2 2026, an estimated $72.5K.
  • Lipocine made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3688 holding.
  • Vanguard Capital Management first reported a position in Lipocine in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Lipocine position peaked at $1.6M in Q1 2026.
  • 34 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.